VEGF Protein (AA 27-191)

Produktnummer ABIN2181903

Dieses Recombinant VEGF-Protein wird in HEK-293 Cells exprimiert und wurde in 3+ Publikationen erwähnt.

Kurzübersicht für VEGF Protein (AA 27-191) (ABIN2181903)

Target: VEGF (Vascular Endothelial Growth Factor (VEGF))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: HEK-293 Cells

Reinheit: >98 % as determined by SDS-PAGE.

Güteklasse: HPLC verified

Produktdetails

Proteineigenschaft: AA 27-191

Marke: ActiveMax®

Sequenz: AA 27-191

Produktmerkmale: This protein carries no "tag". The protein has a calculated MW of 19 kDa (monomer). As a result of glycosylation, the protein migrates as 24 kDa (monomer) under reducing (R) condition, and 43-50 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE).

Sterilität: 0.22 μm filtered

Endotoxin-Niveau: Less than 1.0 EU per μg by the LAL method.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: PBS, pH 7.4

Handhabung: Please avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).

Referenzen

Stumpf, Wimmer, Lorenz, Stieger: "Creation of different bioluminescence resonance energy transfer based biosensors with high affinity to VEGF." in: PLoS ONE, Vol. 15, Issue 3, pp. e0230344, (2020) (PubMed).

Chen, Hsueh, Lee, Tsai, Tsai, Chiang: "FGF primes angioblast formation by inducing ETV2 and LMO2 via FGFR1/BRAF/MEK/ERK." in: Cellular and molecular life sciences : CMLS, (2020) (PubMed).

Keys, Wetter, Hang, Rutschmann, Russo, Mally, Steffen, Zuppiger, Müller, Schneider, Faridmoayer, Lin, Aebi: "A biosynthetic route for polysialylating proteins in Escherichia coli." in: Metabolic engineering, Vol. 44, pp. 293-301, (2018) (PubMed).

Antigendetails

Target: VEGF (Vascular Endothelial Growth Factor (VEGF))

Andere Bezeichnung: VEGF

Hintergrund: VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

Molekulargewicht: 19.2 kDa

NCBI Accession: NP_001165097